Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.49
(1.04%)
AUD 0.49
(1.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.62 Million AUD | -7.2% |
| 2023 | 1.75 Million AUD | -12.49% |
| 2022 | 2 Million AUD | 102.21% |
| 2021 | 990.18 Thousand AUD | -11.34% |
| 2020 | 1.11 Million AUD | 75.99% |
| 2019 | 634.59 Thousand AUD | -22.45% |
| 2018 | 818.3 Thousand AUD | -36.04% |
| 2017 | 1.27 Million AUD | 53.92% |
| 2016 | 831.16 Thousand AUD | 14.33% |
| 2015 | 727.01 Thousand AUD | 147.54% |
| 2014 | 293.69 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 1.62 Million AUD | 0.0% |
| 2024 Q2 | 1.71 Million AUD | 0.0% |
| 2024 FY | 1.62 Million AUD | -7.2% |
| 2023 Q4 | 1.75 Million AUD | 58.88% |
| 2023 FY | 1.75 Million AUD | -12.49% |
| 2023 Q3 | 1.1 Million AUD | -38.75% |
| 2023 Q1 | 1 Million AUD | -49.91% |
| 2023 Q2 | 1.8 Million AUD | 79.55% |
| 2022 Q2 | 1.14 Million AUD | 0.0% |
| 2022 Q4 | 2 Million AUD | 17.66% |
| 2022 FY | 2 Million AUD | 102.21% |
| 2022 Q3 | 1.7 Million AUD | 49.18% |
| 2021 Q4 | 990.18 Thousand AUD | 27.1% |
| 2021 Q3 | 779.03 Thousand AUD | -29.4% |
| 2021 FY | 990.18 Thousand AUD | -11.34% |
| 2021 Q1 | 753.39 Thousand AUD | -32.54% |
| 2021 Q2 | 1.1 Million AUD | 46.46% |
| 2020 Q4 | 1.11 Million AUD | 79.42% |
| 2020 FY | 1.11 Million AUD | 75.99% |
| 2020 Q3 | 622.47 Thousand AUD | -43.26% |
| 2020 Q2 | 1.09 Million AUD | 0.0% |
| 2019 Q3 | 549.07 Thousand AUD | -3.29% |
| 2019 Q4 | 634.59 Thousand AUD | 15.57% |
| 2019 FY | 634.59 Thousand AUD | -22.45% |
| 2019 Q1 | 428.02 Thousand AUD | -47.69% |
| 2019 Q2 | 567.77 Thousand AUD | 32.65% |
| 2018 Q1 | 1.46 Million AUD | 14.8% |
| 2018 Q4 | 818.3 Thousand AUD | 33.9% |
| 2018 FY | 818.3 Thousand AUD | -36.04% |
| 2018 Q2 | 1.46 Million AUD | 0.0% |
| 2018 Q3 | 611.13 Thousand AUD | -58.39% |
| 2017 Q1 | 752.32 Thousand AUD | -9.49% |
| 2017 FY | 1.27 Million AUD | 53.92% |
| 2017 Q4 | 1.27 Million AUD | 0.0% |
| 2017 Q2 | 752.32 Thousand AUD | 0.0% |
| 2017 Q3 | 1.27 Million AUD | 70.05% |
| 2016 Q3 | 831.16 Thousand AUD | 19.92% |
| 2016 Q1 | 693.08 Thousand AUD | -4.67% |
| 2016 FY | 831.16 Thousand AUD | 14.33% |
| 2016 Q4 | 831.16 Thousand AUD | 0.0% |
| 2016 Q2 | 693.08 Thousand AUD | 0.0% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 727.01 Thousand AUD | 0.0% |
| 2015 FY | 727.01 Thousand AUD | 147.54% |
| 2015 Q3 | 727.01 Thousand AUD | 0.0% |
| 2014 FY | 293.69 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -429.878% |
| BTC Health Limited | 203.94 Thousand AUD | -697.225% |
| CSL Limited | 27.88 Billion AUD | 99.994% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 80.485% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 94.216% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -55.498% |
| Orthocell Limited | 22.08 Million AUD | 92.637% |
| Race Oncology Limited | 1.91 Million AUD | 15.158% |
| Starpharma Holdings Limited | 8.69 Million AUD | 81.307% |
| AdAlta Limited | 3.54 Million AUD | 54.103% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 82.623% |
| Memphasys Limited | 5.59 Million AUD | 70.926% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -1797.605% |
| Acrux Limited | 5.68 Million AUD | 71.41% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -341.293% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 56.434% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -38.843% |
| Nyrada Inc. | 855.63 Thousand AUD | -90.026% |
| PharmAust Limited | 896.6 Thousand AUD | -81.342% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 96.361% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 20.943% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 70.033% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 52.553% |
| Biome Australia Limited | 5.37 Million AUD | 69.74% |
| Biotron Limited | 737.5 Thousand AUD | -120.462% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 87.301% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 61.554% |
| Immutep Limited | 10.97 Million AUD | 85.191% |
| Imugene Limited | 33.14 Million AUD | 95.094% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -276.694% |
| Noxopharm Limited | 1.28 Million AUD | -26.176% |
| Patrys Limited | 691.36 Thousand AUD | -135.176% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 30.085% |
| PYC Therapeutics Limited | 10.18 Million AUD | 84.035% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.348% |
| Dimerix Limited | 13.89 Million AUD | 88.297% |
| Hexima Limited | 248.67 Thousand AUD | -553.848% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 96.198% |
| Nanollose Limited | 465.64 Thousand AUD | -249.178% |
| Tissue Repair Ltd | 1.35 Million AUD | -20.358% |
| AnteoTech Limited | 4.07 Million AUD | 60.103% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 54.638% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 89.77% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -72.688% |
| Actinogen Medical Limited | 1.61 Million AUD | -0.654% |
| Immuron Limited | 2.84 Million AUD | 42.76% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 32.999% |